medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/ms2026-183medsovet-10260Research ArticleИНТЕРСТИЦИАЛЬНЫЕ БОЛЕЗНИ ЛЕГКИХINTERSTITIAL LUNG DISEASEПерспективные биологические маркеры в диагностике прогрессирующего легочного фиброза при гиперчувствительном пневмонитеAssociation of MCP-1, VEGF-A, and IL-10 with progressive pulmonary fibrosis in hypersensitivity pneumonitishttps://orcid.org/0000-0001-6257-354XБолотоваЕ. В.BolotovaE. V.

Болотова Елена Валентиновна - д.м.н. профессор кафедры терапии №1 факультета повышения квалификации и последипломной подготовки специалистов.

350063, Россия, Краснодар, ул. Митрофана Седина, д. 4

Elena V. Bolotova - Dr. Sci. (Med.), Professor, Professor of the Department of Therapy No. 1.

4, Mitrofan Sedin St., Krasnodar, 350063

bolotowa_e@mail.ruhttps://orcid.org/0009-0001-0255-2533ЮрковаЮ. Г.YurkovaYu. G.

Юркова Юлия Геннадьевна, аспирант кафедры пульмонологии факультета повышения квалификации и последипломной подготовки специалистов, Кубанский ГМУ; врач-пульмонолог консультативно-диагностического центра, Краевая клиническая больница №1 имени С.В. Очаповского.

350063, Краснодар, ул. Митрофана Седина, д. 4; 350086, Краснодар, ул. 1 Мая, д. 167

Yulia G. Yurkova - Postgraduate Student of the Department of Pulmonology, Kuban SMU; Ochapovsky Regional Clinic Hospital No. 1.

4, Mitrofan Sedin St., Krasnodar, 350063, Pulmonologist; 167, 1st Maya St., Krasnodar, 350086

dr.yurkova.yu@yandex.ruhttps://orcid.org/0000-0002-9766-1811ГилевичИ. В.GilevichI. V.

Гилевич Ирина Валерьевна - к.м.н., заведующая лабораторией разработки и изучения новых технологий лечения заболеваний, Краевая КБ №1 имени С.В. Очаповского; ассистент кафедры онкологии с курсом торакальной хирургии факультета повышения квалификации и последипломной подготовки специалистов, Кубанский ГМУ.

350086, Краснодар, ул. 1 Мая, д. 167; 350063, Краснодар, ул. Митрофана Седина, д. 4

Irina V. Gilevich - Cand. Sci. (Med.), Head of the Laboratory for Development and Study of New Treatment Technologies, Ochapovsky RCH No. 1; Assistant Professor, Department of Oncology with the Course of Thoracic Surgery, Faculty of Advanced Training and Professional Retraining of Specialists, KSMU.

167, 1 Maya St., Krasnodar, 350086; 4, Mitrofan Sedin St., Krasnodar, 350063

giliv@list.ruhttps://orcid.org/0000-0002-2110-0970ШульженкоЛ. В.ShulzhenkoL. V.

Шульженко Лариса Владимировна - д.м.н., заведующая кафедрой пульмонологии факультета повышения квалификации и последипломной подготовки специалистов, Кубанский ГМУ; заведующая пульмонологическим отделением, Краевая КБ №1 имени С.В. Очаповского.

350063, Краснодар, ул. Митрофана Седина, д. 4; 350086, Краснодар, ул. 1 Мая, д. 167

Larisa V. Shulzhenko - Dr. Sci. (Med.), Head of the Department of Pulmonology Kuban SMU; Head of the Department of Pulmonology, Ochapovsky RCH No. 1.

4, Mitrofan Sedin St., Krasnodar, 350063; 167, 1st Maya St., Krasnodar, 350086

larisa_shulzhenko@mail.ruКубанский государственный медицинский университетРоссияKuban State Medical UniversityRussian FederationКубанский государственный медицинский университет; Краевая клиническая больница №1 имени С.В. ОчаповскогоРоссияKuban State Medical University; Ochapovsky Regional Clinic Hospital No. 1Russian Federation20261407202609158164Copyright © Болотова Е.В., Юркова Ю.Г., Гилевич И.В., Шульженко Л.В., 20262026Болотова Е.В., Юркова Ю.Г., Гилевич И.В., Шульженко Л.В.Bolotova E.V., Yurkova Y.G., Gilevich I.V., Shulzhenko L.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/10260Введение

Введение. Гиперчувствительный пневмонит (ГП) и идиопатический легочный фиброз (ИЛФ) в настоящее время являются наиболее распространенными прогрессирующими легочными фиброзами (ПЛФ), течение которых определяет развитие прогрессирующей дыхательной недостаточности и плохой прогноз у пациентов. В настоящее время продолжается поиск лабораторных маркеров ПЛФ, к которым относятся моноцитарный хемоаттрактантный протеин-1 (MCP-1), фактор роста эндотелия сосудов (VEGF-А) и интерлейкин-10 (IL-10).

Цель

Цель. Изучить взаимосвязь MCP-1, VEGF-А и IL-10 в сыворотке крови с критериями ПЛФ у пациентов с ГП.

Материалы и методы

Материалы и методы. В исследование включены 51 пациент с ГП и 12 пациентов с идиопатическим легочным фиброзом (ИЛФ), диагноз ПЛФ установлен на основании критериев диагностики Американского торакального общества 2022 г. Средний возраст пациентов составил 61,7 ± 10,6 года. Количественное определение уровня MCP-1, VEGF-А и IL-10 в сыворотке крови выполнено на иммуноферментном анализаторе Hydro Flex (TECAN, Австрия) с помощью наборов Вектор-Бест (Россия).

Результаты

Результаты. Исходные уровни MCP-1 были достоверно выше при ИЛФ и ГП с ПЛФ (291,3 ± 68,4 vs 270,9 ± 54,2 пг/мл) в сравнении ГП без ПЛФ (220,9 ± 42,8 пг/мл; p = 0,005 и р = 0,008). Выявлена отрицательная корреляция между уровнями MCP-1 и IL-10 с динамикой ФЖЕЛ и DLCO за 12 мес.

Заключение

Заключение. Повышение уровней MCP-1 и IL-10 в сыворотке крови при ГП с ПЛФ статистически значимо связано со снижением ФЖЕЛ ≥ 5% и DLCO ≥ 10% в течение 12 мес.

Introduction

Introduction. Hypersensitivity pneumonitis (HP) is the most common interstitial lung disease (ILD), which is characterized by the development of progressive pulmonary fibrosis (PPF).

Aim

Aim. To study the relationship between monocyte chemoattractant protein-1 (MCP-1), vascular endothelial growth factor (VEGF-A) and interleukin-10 (IL-10) in serum and PPF criteria in patients with HP.

Materials and methods

Materials and methods. The study included 51 patients with GP, the diagnosis of PPF was established based on the diagnostic criteria of the American Thoracic Society (2022), and 12 patients with idiopathic pulmonary fibrosis (IPF). Quantitative determination of the level of MCP-1, VEGF-A and IL-10 in the blood serum was performed using Vector-Best kits (Russia) on the enzyme immunoassay analyzer “Hydro Flex” (TECAN, Austria). Statistical data processing was performed using Statistica 10.0 software.

Results

Results. Baseline levels of MCP-1 and IL-10 (7.11 ± 2.26 vs. 6.53 ± 2.62 pg/ml) in the blood serum were comparable in IPF and GP with PPF (p = 0.36 and p = 0.18, respectively). MCP-1 levels were significantly higher in IPF and GP with PPF (291.3 ± 68.4 vs. 270.9 ± 54.2 pg/ml) compared to GP without PFF (220,9 ± 42,8 pg/ml; p = 0.005 and p = 0.008). A negative correlation was found between MCP-1 and IL-10 levels and dynamics FVC and DLCO over 12 months.

Conclusion

Conclusion. Increased serum MCP-1 and IL-10 levels in patients with PPF in GP are statistically significantly associated with a decrease in FVC ≥ 5% and DLCO ≥ 10% over a 12-month period.

гиперчувствительный пневмонитпрогрессирующий легочный фиброзMCP-1IL-10VEGF-Аhypersensitivity pneumonitisprogressive pulmonary fibrosisMCP-1IL-10VEGF-АИсследование выполнено при поддержке администрации ГБУЗ «Научно-исследовательский институт – Краевая клиническая больница №1 имени С.В. Очаповского»The study was carried out with the support of the administration of the State Budgetary Healthcare Institution “Research Institute – Regional Clinical Hospital No. 1 named after S.V. Ochapovsky”ReferencesАвдеев СН, Айсанов ЗР, Визель АА, Демко ИВ, Илькович ММ, Киняйкин МФ и др. Гиперчувствительный пневмонит: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2025;35(1):16–41. https://doi.org/10.18093/0869-0189-2025-35-1-16-41.Avdeev SN, Aisanov ZR, Vizel AA, Demko IV, Ilkovich MM, Kiniaikin MF et al. Federal clinical guidelines on diagnosis and treatment of hypersensitivity pneumonitis. Pulmonologiya. 2025;35(1):16–41. (In Russ.) https://doi.org/10.18093/0869-0189-2025-35-1-16-41.Авдеев СН, Чикина СЮ, Тюрин ИЕ, Белевский АС, Терпигорев СА, Ананьева ЛП и др. Хронические фиброзирующие интерстициальные заболевания легких с прогрессирующим фиброзным фенотипом: резолюция Междисциплинарного Совета экспертов. Пульмонология. 2021;31(4):505–510. https://doi.org/10.18093/0869-0189-2021-31-4-505-510.Avdeev SN, Chikina SYu, Tyurin IE, Belevskiy AS, Terpigorev SA, Anan’yeva LP et al. Chronic fibrosing progressing interstitial lung disease: a decision of Multidisciplinary Expert Board. Pulmonologiya. 2021;31(4):505–510. (In Russ.) https://doi.org/10.18093/0869-0189-2021-31-4-505-510.Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M et al. Diagnosis of hypersensitivity pneumonitis in adults. An Official ATS/JRS/ ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(3):e36–69. https://doi.org/10.1164/rccm.202005-2032st.Raghu G, Remy-Jardin M, Ryerson CJ, Myers JL, Kreuter M, Vasakova M et al. Diagnosis of hypersensitivity pneumonitis in adults. An Official ATS/JRS/ ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(3):e36–69. https://doi.org/10.1164/rccm.202005-2032st.Olson AL, Gifford AH, Inase N, Fernández Pérez ER, Suda T. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur Respir Rev. 2018;27(150):180077. https://doi.org/10.1183/16000617.0077-2018.Olson AL, Gifford AH, Inase N, Fernández Pérez ER, Suda T. The epidemiology of idiopathic pulmonary fibrosis and interstitial lung diseases at risk of a progressive-fibrosing phenotype. Eur Respir Rev. 2018;27(150):180077. https://doi.org/10.1183/16000617.0077-2018.Raghu G, Richeldi L, Jagerschmidt A, Martin V, Subramaniam A, Ozoux ML et al. Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers. Chest. 2018;154(6):1359–1370. https://doi.org/10.1016/j.chest.2018.08.1083.Raghu G, Richeldi L, Jagerschmidt A, Martin V, Subramaniam A, Ozoux ML et al. Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers. Chest. 2018;154(6):1359–1370. https://doi.org/10.1016/j.chest.2018.08.1083.Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718–1727. https://doi.org/10.1056/NEJMoa1908681.Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. 2019;381(18):1718–1727. https://doi.org/10.1056/NEJMoa1908681.Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18–e47. https://doi.org/10.1164/rccm.202202-0399ST.Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):e18–e47. https://doi.org/10.1164/rccm.202202-0399ST.Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J. 2022;60(4):2102571. https://doi.org/10.1183/13993003.02571-2021.Hambly N, Farooqi MM, Dvorkin-Gheva A, Donohoe K, Garlick K, Scallan C et al. Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry. Eur Respir J. 2022;60(4):2102571. https://doi.org/10.1183/13993003.02571-2021.Нашатырева МС, Трофименко ИН, Черняк БА. Хронические фиброзирующие интерстициальные заболевания легких по данным регистра больных, проживающих в Иркутске (Россия). Пульмонология. 2022;32(2):199–207. https://doi.org/10.18093/0869-0189-2022-32-2-199-207.Nashatyreva MS, Trofimenko IN, Chernyak BA. Chronic fibrosing interstitial lung diseases according to the register of Irkutsk (Russia). Pulmonologiya. 2022;32(2):199–207. (In Russ.) https://doi.org/10.18093/0869-0189-2022-32-2-199-207.Nashatyreva MS, Trofimenko IN, Chernyak BA, Avdeev SN. Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in a Prospective Registry of Interstitial Lung Diseases in Eastern Siberia. Life. 2023;13(1):212. https://doi.org/10.3390/life13010212.Nashatyreva MS, Trofimenko IN, Chernyak BA, Avdeev SN. Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in a Prospective Registry of Interstitial Lung Diseases in Eastern Siberia. Life. 2023;13(1):212. https://doi.org/10.3390/life13010212.Bowman WS, Newton CA, Linderholm AL, Neely ML, Pugashetti JV, Kaul B et al. Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis. Lancet Respir Med. 2022;10(6):593–602. https://doi.org/10.1016/S2213-2600(21)00503-8.Bowman WS, Newton CA, Linderholm AL, Neely ML, Pugashetti JV, Kaul B et al. Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis. Lancet Respir Med. 2022;10(6):593–602. https://doi.org/10.1016/S2213-2600(21)00503-8.Wang J, Zhang L, Luo L, He P, Xiong A, Jiang M et al. Characterizing cellular heterogeneity in fibrotic hypersensitivity pneumonitis by single-cell transcriptional analysis. Cell Death Discov. 2022;8(1):38. https://doi.org/10.1038/s41420-022-00831-x.Wang J, Zhang L, Luo L, He P, Xiong A, Jiang M et al. Characterizing cellular heterogeneity in fibrotic hypersensitivity pneumonitis by single-cell transcriptional analysis. Cell Death Discov. 2022;8(1):38. https://doi.org/10.1038/s41420-022-00831-x.Bowman WS, Echt GA, Oldham JM. Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response. Front Med. 2021;8:680997. https://doi.org/10.3389/fmed.2021.680997.Bowman WS, Echt GA, Oldham JM. Biomarkers in Progressive Fibrosing Interstitial Lung Disease: Optimizing Diagnosis, Prognosis, and Treatment Response. Front Med. 2021;8:680997. https://doi.org/10.3389/fmed.2021.680997.Kishore A, Petrek M. Roles of Macrophage Polarization and Macrophage-Derived miRNAs in Pulmonary Fibrosis. Front Immunol. 2021;12:678457. https://doi.org/10.3389/fimmu.2021.678457.Kishore A, Petrek M. Roles of Macrophage Polarization and Macrophage-Derived miRNAs in Pulmonary Fibrosis. Front Immunol. 2021;12:678457. https://doi.org/10.3389/fimmu.2021.678457.Lou Y, Zheng Y, Fan B, Zhang L, Zhu F, Wang X et al. Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease. BMC Pulm Med. 2020;20(1):196. https://doi.org/10.1186/s12890-020-01226-3.Lou Y, Zheng Y, Fan B, Zhang L, Zhu F, Wang X et al. Serum levels of interleukins and S100A8/A9 correlate with clinical severity in patients with dermatomyositis-associated interstitial lung disease. BMC Pulm Med. 2020;20(1):196. https://doi.org/10.1186/s12890-020-01226-3.Shih LJ, Yang CC, Liao MT, Lu KC, Hu WC, Lin CP. An important call: Suggestion of using IL-10 as therapeutic agent for COVID-19 with ARDS and other complications. Virulence. 2023;14(1):2190650. https://doi.org/10.1080/21505594.2023.2190650.Shih LJ, Yang CC, Liao MT, Lu KC, Hu WC, Lin CP. An important call: Suggestion of using IL-10 as therapeutic agent for COVID-19 with ARDS and other complications. Virulence. 2023;14(1):2190650. https://doi.org/10.1080/21505594.2023.2190650.Steen EH, Wang X, Balaji S, Butte MJ, Bollyky PL, Keswani SG. The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis. Adv Wound Care. 2020;9(4):184–198. https://doi.org/10.1089/wound.2019.1032.Steen EH, Wang X, Balaji S, Butte MJ, Bollyky PL, Keswani SG. The Role of the Anti-Inflammatory Cytokine Interleukin-10 in Tissue Fibrosis. Adv Wound Care. 2020;9(4):184–198. https://doi.org/10.1089/wound.2019.1032.Pulito-Cueto V, Remuzgo-Martínez S, Genre F, Atienza-Mateo B, Mora-Cuesta VM, Iturbe-Fernández D et al. Elevated VCAM-1, MCP-1 and ADMA serum levels related to pulmonary fibrosis of interstitial lung disease associated with rheumatoid arthritis. Front Mol Biosci. 2022;9:1056121. https://doi.org/10.3389/fmolb.2022.1056121.Pulito-Cueto V, Remuzgo-Martínez S, Genre F, Atienza-Mateo B, Mora-Cuesta VM, Iturbe-Fernández D et al. Elevated VCAM-1, MCP-1 and ADMA serum levels related to pulmonary fibrosis of interstitial lung disease associated with rheumatoid arthritis. Front Mol Biosci. 2022;9:1056121. https://doi.org/10.3389/fmolb.2022.1056121.Singh S, Anshita D, Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol. 2021;101(Pt B):107598. https://doi.org/10.1016/j.intimp.2021.107598.Singh S, Anshita D, Ravichandiran V. MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol. 2021;101(Pt B):107598. https://doi.org/10.1016/j.intimp.2021.107598.Попова ЕН, Лебедева МВ, Пономарев АБ, Попова ИА, Фомин ВВ. Интерстициальный фиброз легких: роль факторов ангиогенеза, пути торможения прогрессирования. Терапевтический архив. 2014;86(8):23–28. Режим доступа: https://cyberleninka.ru/article/n/interstitsialnyy-fibroz-legkihrol-faktorov-angiogeneza-puti-tormozheniya-progressirovaniya/viewer.Popova EN, Lebedeva MV, Ponomarev AB, Popova IA, Fomin VV. Interstitial pulmonary fibrosis: The role of angiogenic factors, the inhibitory pathways of progression. Terapevticheskii Arkhiv. 2014;86(8):23–28. (In Russ.) Available at: https://cyberleninka.ru/article/n/interstitsialnyy-fibroz-legkih-rol-faktorov-angiogeneza-puti-tormozheniya-progressirovaniya/viewer.Abdelhady R, Cavalu S, Saber S, Elmowafy R, Morsy NE, Ibrahim S et al. Mirtazapine, an atypical antidepressant, mitigates lung fibrosis by suppressing NLPR3 inflammasome and fibrosis-related mediators in endotracheal bleomycin rat model. Biomed Pharmacother. 2023;161:114553. https://doi.org/10.1016/j.biopha.2023.114553.Abdelhady R, Cavalu S, Saber S, Elmowafy R, Morsy NE, Ibrahim S et al. Mirtazapine, an atypical antidepressant, mitigates lung fibrosis by suppressing NLPR3 inflammasome and fibrosis-related mediators in endotracheal bleomycin rat model. Biomed Pharmacother. 2023;161:114553. https://doi.org/10.1016/j.biopha.2023.114553.Guilherme RF, Silva JBNF, Waclawiack I, Fraga-Junior VS, Nogueira TO, Pecli C et al. Pleiotropic antifibrotic actions of aspirin-triggered resolvin D1 in the lungs. Front Immunol. 2023;14:886601. https://doi.org/10.3389/fimmu.2023.886601.Guilherme RF, Silva JBNF, Waclawiack I, Fraga-Junior VS, Nogueira TO, Pecli C et al. Pleiotropic antifibrotic actions of aspirin-triggered resolvin D1 in the lungs. Front Immunol. 2023;14:886601. https://doi.org/10.3389/fimmu.2023.886601.Трушенко НВ, Николенко АМ, Суворова ОА, Авдеев СН. Биомаркеры и генетические предикторы при гиперчувствительном пневмоните. Пульмонология. 2024;34(6):896–903. https://doi.org/10.18093/0869-0189-2024-34-6-896-903.Trushenko NV, Nikolenko AM, Suvorova OA, Avdeev SN. Biomarkers and genetic predictors of hypersensitivity pneumonitis. Pulmonologiya. 2024;34(6):896–903. (In Russ.) https://doi.org/10.18093/0869-0189-2024-34-6-896-903.Trushenko NV, Suvorova OA, Pershina ES, Nekludova GV, Chikina SY, Levina IA et al. Predictors of Progression and Mortality in Patients with Chronic Hypersensitivity Pneumonitis: Retrospective Analysis of Registry of Fibrosing Interstitial Lung Diseases. Life. 2023;13(2):467. https://doi.org/10.3390/life13020467.Trushenko NV, Suvorova OA, Pershina ES, Nekludova GV, Chikina SY, Levina IA et al. Predictors of Progression and Mortality in Patients with Chronic Hypersensitivity Pneumonitis: Retrospective Analysis of Registry of Fibrosing Interstitial Lung Diseases. Life. 2023;13(2):467. https://doi.org/10.3390/life13020467.Gui X, Qiu X, Tian Y, Xie M, Li H, Gao Y et al. Prognostic value of IFN-γ, sCD163, CCL2 and CXCL10 involved in acute exacerbation of idiopathic pulmonary fibrosis. Int Immunopharmacol. 2019;70:208–215. https://doi.org/10.1016/j.intimp.2019.02.039.Gui X, Qiu X, Tian Y, Xie M, Li H, Gao Y et al. Prognostic value of IFN-γ, sCD163, CCL2 and CXCL10 involved in acute exacerbation of idiopathic pulmonary fibrosis. Int Immunopharmacol. 2019;70:208–215. https://doi.org/10.1016/j.intimp.2019.02.039.Kalafatis D, Löfdahl A, Näsman P, Dellgren G, Wheelock ÅM, Elowsson Rendin L et al. Distal Lung Microenvironment Triggers Release of Mediators Recognized as Potential Systemic Biomarkers for Idiopathic Pulmonary Fibrosis. Int J Mol Sci. 2021;22(24):13421. https://doi.org/10.3390/ijms222413421.Kalafatis D, Löfdahl A, Näsman P, Dellgren G, Wheelock ÅM, Elowsson Rendin L et al. Distal Lung Microenvironment Triggers Release of Mediators Recognized as Potential Systemic Biomarkers for Idiopathic Pulmonary Fibrosis. Int J Mol Sci. 2021;22(24):13421. https://doi.org/10.3390/ijms222413421.

The authors declare that there are no conflicts of interest present.